Circulating miR-221/222 reduces CD4+ T cells by inhibiting CD4 expression in colorectal cancer
Circulating miR-221/222 reduces CD4+ T cells by inhibiting CD4 expression in colorectal cancer
复制标题
循环中的 miR-221/222 通过抑制结直肠癌中的 CD4 表达来减少 CD4 T 细胞
DOI：
10.1093/abbs/gmab106
复制
发表时间：
2021-08-06
影响因子：
3.7
通讯作者：
Liu, Sanhong
中科院分区：
文献类型：
--
作者：
Hu, Jiajia;Zhang, Jiawei;Liu, Sanhong
许多癌症患者的外周血中CD 4（+）水平较低。然而，其分子机制尚不清楚。在这里，我们发现miR-221和miR-222的血液水平在结直肠癌（CRC）患者中显著增加，循环miR-211和miR-222都是敏感的诊断标志物，曲线下面积分别为0.8790和0.9148。转染miR-221或miR-222导致表面CD 4抗原水平降低，但不导致表面CD 8抗原水平降低。荧光素酶报告基因分析显示miR-221/222直接调节人原代T细胞中的CD 4表达。这些数据表明，miR-221/222水平在CRC患者的血液中上调，并且miR-221/222抑制人原代T细胞中CD 4的表达。这些发现为调节血液中CD 4（+）T细胞的数量并进一步调整适合免疫治疗的微环境提供了一种新策略。
Many patients with cancers have low levels of CD4(+) in their peripheral blood. However, the molecular mechanism is still unclear. Here, we found that the blood levels of miR-221 and miR-222 were dramatically increased in patients with colorectal cancer (CRC), and both circulating miR-211 and miR-222 served as sensitive diagnostic markers with an area under the curve of 0.8790 and 0.9148, respectively. Transfection of either miR-221 or miR-222 resulted in the reduction of the surface CD4 antigen level but not the surface CD8 antigen level. The luciferase reporter assay showed that miR-221/222 directly regulated CD4 expression in human primary T cells. These data showed that miR-221/222 levels were upregulated in the blood of patients with CRC and that the expression of CD4 in human primary T cells was inhibited by miR-221/222. These findings provide a novel strategy for modulating the number of CD4(+) T cells in the blood and further adjusting the microenvironment suitable for immunotherapy.